(RTTNews) - Boston Scientific Corp (BSX:
News ) said it has received 510(k) clearance from the U.S. Food and Drug Administration and CE Mark approval to market its WallFlex Fully Covered Esophageal Stent for the treatment of malignant esophageal strictures caused by tumors in patients with resectable or non-resectable esophageal cancer.
The WallFlex Partially Covered Esophageal Stent was cleared by the FDA and received CE Mark in 2008.
Click here to receive FREE breaking news email alerts for Boston Scientific Corp and others in your portfolio
by RTT Staff Writer
For comments and feedback: contact editorial@rttnews.com